Key Highlights
- BioCryst Pharmaceuticals shares were up 6.93% in pre-market trading to $9.65, extending Tuesday's 2.38% close gain to $9.02.
- Second-quarter total revenue reached $218.2 million, well above the $183.3 million analyst estimate.
- ORLADEYO net revenue grew to $158.2 million, up 1% year-over-year on a reported basis and up 10% on a comparable basis excluding prior European revenue.
- The company affirmed full-year 2026 global ORLADEYO net revenue guidance of $625 million to $645 million, slightly below the $666.2 million consensus.
- Initial shipments of ORLADEYO oral pellets to pediatric patients began the week of August 3, marking a new treatment paradigm for hereditary angioedema in children.
What's Driving the Gain
BioCryst Pharmaceuticals (NASDAQ:BCRX) is a Durham, North Carolina-based biotechnology company founded in 1986 that leverages structure-guided drug design to discover and develop oral small-molecule and injectable protein therapeutics for rare and serious diseases. Its commercial portfolio is anchored by ORLADEYO (berotralstat), the first oral, once-daily plasma kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema, alongside RAPIVAB, an intravenous neuraminidase inhibitor for influenza.
Shares are surging in pre-market trading after the company reported second-quarter revenue of $218.2 million, well above the $183.3 million analyst estimate, driven by continued ORLADEYO sales momentum. The beat comes even as BioCryst affirmed its full-year 2026 sales guidance of $635 million to $660 million in total revenue, a range that sits slightly below the $666.2 million consensus, suggesting the quarterly outperformance may not fully translate into raised full-year expectations.
Pediatric Launch and Pharmacy Transition
A key development during the quarter was the start of initial ORLADEYO oral pellet shipments to pediatric patients the week of August 3, opening a new treatment avenue for children with hereditary angioedema following FDA approval of the pediatric indication. To support the growing scale of ORLADEYO across both adult and pediatric populations, BioCryst has engaged CareMed as its new commercial pharmacy partner, which will become the company's sole-source specialty pharmacy for ORLADEYO shipments beginning in the third quarter of 2026.
New patient prescriptions maintained momentum during the quarter, supporting the 10% year-over-year growth in ORLADEYO revenue on a comparable basis that excludes the impact of the company's prior European business, which was sold as part of a broader restructuring of its international operations.
Rally Comes Amid Broader Risk-On Backdrop
The rally arrives alongside a broader risk-on move across biotech and healthcare stocks this week, as easing Middle East tensions and falling oil prices have lifted equity markets to record highs. With shares still down roughly 10% over the prior month amid valuation concerns, some of today's gain may also reflect a broader sector recovery rather than the earnings beat in isolation.
Conclusion
BioCryst's second-quarter revenue beat, combined with the successful start of its pediatric ORLADEYO launch, suggests the company's core hereditary angioedema franchise continues to expand even as full-year guidance was left unchanged. Investors will likely be watching subsequent quarters closely to see whether the pediatric expansion and new pharmacy partnership translate into guidance upside later in the year.
This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.






Please wait processing your request...